Epigallocatechin ( DrugBank: Epigallocatechin )

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
8	ハンチントン病	1
13	多発性硬化症／視神経脊髄炎	4
28	全身性アミロイドーシス	2
85	特発性間質性肺炎	2
113	筋ジストロフィー	2

8. ハンチントン病

臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01357681 (ClinicalTrials.gov)	September 2011	19/5/2011	Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)	Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease The ETON-Study - A Randomized, Double-blind, Stratified, Placebo-controlled Prospective Investigator Initiated Multicenter Trial -	Huntington Disease	Drug: (2)-epigallocatechin-3-gallate (EGCG);Drug: Placebo	Charite University, Berlin, Germany	NULL	Completed	18 Years	N/A	Both	54	Phase 2	Germany

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03740295 (ClinicalTrials.gov)	October 5, 2018	5/10/2018	Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis	Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis	Multiple Sclerosis	Dietary Supplement: Coconut oil and epigallocatechin gallate;Other: Placebo	Fundación Universidad Católica de Valencia San Vicente Mártir	Valencian Institute of Neurorehabilitation Foundation	Completed	19 Years	65 Years	All	60	Phase 2	Spain
2	NCT00799890 (ClinicalTrials.gov)	May 2009	28/11/2008	Sunphenon in Progressive Forms of Multiple Sclerosis	Monocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Evaluate the Effect of Sunphenon EGCg (Main Component Epigallocatechin-Gallat) on the Increase of Brain Atrophy in the Cerebral Magnetic Resonance Tomography in a 36-months Treatment Time in Patients With Primary or Secondary Chronic-progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Sunphenon EGCG;Drug: Placebo	Friedemann Paul	TAIYO EUROPE	Completed	18 Years	65 Years	All	61	Phase 2/Phase 3	Germany
3	NCT00525668 (ClinicalTrials.gov)	September 2007	4/9/2007	Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)	Sunphenon EGCg (Epigallocatechin-gallate) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)	Relapsing-remitting Multiple Sclerosis	Drug: epigallocatechin-gallate (Sunphenon);Drug: placebo	Charite University, Berlin, Germany	NULL	Completed	18 Years	60 Years	All	120	Phase 1/Phase 2	Germany
4	EUCTR2006-006323-39-DE (EUCTR)	19/06/2007	05/03/2007	Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MS	Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MS	relapsing-remitting multiple sclerosisICD classification: G35.1	Product Name: Sunphenon Other descriptive name: Sunphenon EGCg TM	Charité-Universitätsmedizin Berlin	NULL	Not Recruiting			Female: yes Male: yes	100		Germany

28. 全身性アミロイドーシス

臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02015312 (ClinicalTrials.gov)	April 2013	18/11/2013	A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)	A Randomised Trial for the Treatment of Cardiac AMyloid Light-chain Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)	Light Chain (AL) Amyloidosis;Cardiac Involvement	Drug: Epigallocatechin-3-gallate (EGCG);Drug: Placebo	Florian Michel	German Federal Ministry of Education and Research	Completed	18 Years	N/A	All	38	Phase 2	Germany
2	NCT01511263 (ClinicalTrials.gov)	January 2012	10/1/2012	Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis	A Phase II Open-label Randomized Study of Dietary Supplement With Epigallocatechin Gallate (EGCG) to Improve Cardiac Dysfunction in Patients With AL Amyloidosis Who do Not Require Chemotherapy (EpiCardiAL)	Primary Amyloidosis of Light Chain Type	Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias);Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG	IRCCS Policlinico S. Matteo	NULL	Terminated	18 Years	N/A	All	86	Phase 2	Italy

85. 特発性間質性肺炎

臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05195918 (ClinicalTrials.gov)	March 1, 2023	2/12/2021	Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients	Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients With Idiopathic Pulmonary Fibrosis (IPF) Evaluating Safety, PK Interactions With Standard of Care Drugs, and Biomarkers of Drug Effect	Idiopathic Pulmonary Fibrosis	Combination Product: EGCG 300 mg + Nintedanib;Combination Product: EGCG 300 mg + Pirfenidone;Combination Product: Placebo 2 capsules + Nintedanib or Pirfenidone;Combination Product: EGCG 600 mg + Nintedanib;Combination Product: EGCG 600 mg + Pirfenidone;Combination Product: Placebo 4 capsules + Nintedanib or Pirfenidone	Hal Chapman	University of Michigan;Cornell University;Massachusetts General Hospital;Temple University;University of Washington	Not yet recruiting	40 Years	85 Years	All	50	Phase 1	United States
2	NCT03928847 (ClinicalTrials.gov)	December 1, 2017	18/4/2019	Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.	Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.	Idiopathic Pulmonary Fibrosis	Drug: Epigallocatechin-3-gallate (EGCG)	Hal Chapman	National Heart, Lung, and Blood Institute (NHLBI)	Completed	40 Years	70 Years	All	35	Early Phase 1	United States

113. 筋ジストロフィー

臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01183767 (ClinicalTrials.gov)	December 30, 2010	17/8/2010	Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy	Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy	Duchenne Muscular Dystrophy	Drug: Epigallocatechin-Gallate;Drug: Placebo	Charite University, Berlin, Germany	NULL	Completed	5 Years	10 Years	All	33	Phase 2/Phase 3	Germany
2	EUCTR2009-016482-28-DE (EUCTR)	25/06/2010	15/03/2010	SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular Dystrophy	SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular Dystrophy - SUNIMUD	Duchenne Muscular Dystrophy;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Sunphenon EGCG INN or Proposed INN: Sunphenon	Charite Universitätsmedizin Berlin	NULL	Not Recruiting			Female: no Male: yes	40	Phase 2	Germany

先頭へ